NASDAQ:ARVN

Arvinas Stock Forecast, Price & News

$63.00
+0.11 (+0.17 %)
(As of 04/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$62.22
Now: $63.00
$64.70
50-Day Range
$58.19
MA: $68.74
$78.30
52-Week Range
$19.68
Now: $63.00
$92.77
Volume243,911 shs
Average Volume486,607 shs
Market Capitalization$3.08 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.14
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.
Arvinas logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ARVN
CUSIPN/A
CIKN/A
Phone(203) 535-1456
Employees133
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$42.98 million
Book Value$6.72 per share

Profitability

Net Income$-70,290,000.00
Net Margins-403.77%

Miscellaneous

Market Cap$3.08 billion
Next Earnings Date4/27/2021 (Estimated)
OptionableNot Optionable

Headlines

Is ARVN Stock A Buy or Sell? - Yahoo Finance
April 12, 2021 |  finance.yahoo.com
Is ARVN Stock A Buy or Sell?
April 12, 2021 |  finance.yahoo.com
Arvinas (NASDAQ:ARVN) Now Covered by BMO Capital Markets
March 31, 2021 |  americanbankingnews.com
See More Headlines

MarketRank

Overall MarketRank

1.51 out of 5 stars

Medical Sector

497th out of 2,021 stocks

Pharmaceutical Preparations Industry

239th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
$63.00
+0.11 (+0.17 %)
(As of 04/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ARVN News and Ratings via Email

Sign-up to receive the latest news and ratings for ARVN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Arvinas (NASDAQ:ARVN) Frequently Asked Questions

Is Arvinas a buy right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Arvinas stock.
View analyst ratings for Arvinas
or view top-rated stocks.

What stocks does MarketBeat like better than Arvinas?

Wall Street analysts have given Arvinas a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Arvinas wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Arvinas' next earnings date?

Arvinas is scheduled to release its next quarterly earnings announcement on Tuesday, April 27th 2021.
View our earnings forecast for Arvinas
.

How were Arvinas' earnings last quarter?

Arvinas, Inc. (NASDAQ:ARVN) issued its quarterly earnings results on Sunday, February, 28th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.78) by $0.21. The business earned $2.22 million during the quarter, compared to the consensus estimate of $7.46 million. Arvinas had a negative net margin of 403.77% and a negative trailing twelve-month return on equity of 46.99%.
View Arvinas' earnings history
.

How has Arvinas' stock been impacted by Coronavirus (COVID-19)?

Arvinas' stock was trading at $44.06 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ARVN stock has increased by 43.0% and is now trading at $63.00.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ARVN?

9 analysts have issued 12-month target prices for Arvinas' shares. Their forecasts range from $45.00 to $140.00. On average, they expect Arvinas' share price to reach $106.45 in the next twelve months. This suggests a possible upside of 69.0% from the stock's current price.
View analysts' price targets for Arvinas
or view top-rated stocks among Wall Street analysts.

Who are Arvinas' key executives?

Arvinas' management team includes the following people:
  • John G. Houston, President, Chief Executive Officer & Director
  • Sean A. Cassidy, Chief Financial Officer
  • Ian Taylor, Chief Scientific Officer
  • Ronald Peck, Chief Medical Officer
  • Kimberly Wehger, Vice President-Information Technology

Who are some of Arvinas' key competitors?

What other stocks do shareholders of Arvinas own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Pfizer (PFE), CRISPR Therapeutics (CRSP), Energy Transfer (ET), OPKO Health (OPK), Advanced Micro Devices (AMD), Enphase Energy (ENPH), Fortress Biotech (FBIO) and Gilead Sciences (GILD).

When did Arvinas IPO?

(ARVN) raised $100 million in an IPO on Thursday, September 27th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray served as the underwriters for the IPO.

What is Arvinas' stock symbol?

Arvinas trades on the NASDAQ under the ticker symbol "ARVN."

How do I buy shares of Arvinas?

Shares of ARVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arvinas' stock price today?

One share of ARVN stock can currently be purchased for approximately $63.00.

How much money does Arvinas make?

Arvinas has a market capitalization of $3.08 billion and generates $42.98 million in revenue each year. The company earns $-70,290,000.00 in net income (profit) each year or ($2.13) on an earnings per share basis.

How many employees does Arvinas have?

Arvinas employs 133 workers across the globe.

What is Arvinas' official website?

The official website for Arvinas is www.arvinas.com.

Where are Arvinas' headquarters?

Arvinas is headquartered at 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511.

How can I contact Arvinas?

Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The company can be reached via phone at (203) 535-1456 or via email at [email protected]


This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.